Abstract
Idiopathic pulmonary fibrosis (IPF) is a chronic condition of unknown etiology with deteriorating respiratory function leading to respiratory failure. Corticosteroids, alone or in combination with immunosuppressive drugs such as azathioprine, colchicine, and cyclophosphamide, have been used with limited success. Interferon-gamma-1b showed a significant improvement in pulmonary function only in one study. Pirfenidone, cyclosporine and acetylcysteine may also be of benefit but data from studies are limited. Novel drugs, mainly antifibrotic, anticytokine and immunoregulatory, are currently being investigated in various trial phases. Endothelin receptor antagonists have been shown to have possible beneficial effects in early stages of IPF. However, most recently, the so-called triple combination therapy, anticoagulation therapy and endothelin receptor antagonists, especially ambrisentan, are either harmful or ineffective in IPF and are not recommended. We report a brief review on the present and possible future therapeutic options in IPF.
Keywords: Ambrisentan, bosentan, cyclophosphamide, hypertension, idiopatic pulmonary fibrosis, iloprost, pulmonary pulmonary fibrosis, pirfenidone, sildenafil.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Novelty in Treatment of Pulmonary Fibrosis: Pulmonary Hypertension Drugs and Others
Volume: 11 Issue: 3
Author(s): Michele Correale, Antonio Totaro, Donato Lacedonia, Deodata Montrone, Matteo Di Biase, Maria Pia Barbaro Foschino and Natale Daniele Brunetti
Affiliation:
Keywords: Ambrisentan, bosentan, cyclophosphamide, hypertension, idiopatic pulmonary fibrosis, iloprost, pulmonary pulmonary fibrosis, pirfenidone, sildenafil.
Abstract: Idiopathic pulmonary fibrosis (IPF) is a chronic condition of unknown etiology with deteriorating respiratory function leading to respiratory failure. Corticosteroids, alone or in combination with immunosuppressive drugs such as azathioprine, colchicine, and cyclophosphamide, have been used with limited success. Interferon-gamma-1b showed a significant improvement in pulmonary function only in one study. Pirfenidone, cyclosporine and acetylcysteine may also be of benefit but data from studies are limited. Novel drugs, mainly antifibrotic, anticytokine and immunoregulatory, are currently being investigated in various trial phases. Endothelin receptor antagonists have been shown to have possible beneficial effects in early stages of IPF. However, most recently, the so-called triple combination therapy, anticoagulation therapy and endothelin receptor antagonists, especially ambrisentan, are either harmful or ineffective in IPF and are not recommended. We report a brief review on the present and possible future therapeutic options in IPF.
Export Options
About this article
Cite this article as:
Correale Michele, Totaro Antonio, Lacedonia Donato, Montrone Deodata, Biase Di Matteo, Foschino Pia Barbaro Maria and Brunetti Daniele Natale, Novelty in Treatment of Pulmonary Fibrosis: Pulmonary Hypertension Drugs and Others , Cardiovascular & Hematological Agents in Medicinal Chemistry 2013; 11 (3) . https://dx.doi.org/10.2174/187152571131100086
DOI https://dx.doi.org/10.2174/187152571131100086 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Do Human Lipoxygenases have a PDZ Regulatory Domain?
Current Molecular Medicine Pleiotropic Effects of the Rho-kinase Inhibitor Fasudil After Subarachnoid Hemorrhage: A Review of Preclinical and Clinical Studies
Current Vascular Pharmacology Teenage-Pregnancies - A Biomedical and a Sociocultural Approach to a Current Problem
Current Women`s Health Reviews Impact of Dendritic Cells on Vascular Biology
Current Hypertension Reviews Myocardial Contrast Echocardiography: Role in Clinical Cardiology
Current Vascular Pharmacology Management of Blood Pressure and Heart Rate in Chronic Kidney Disease
Current Pharmaceutical Design Editorial [Hot topic: Phosphodiesterase-5 Inhibitors and their Use in the Treatment of Urological Conditions (Executive Editor: Perimenis Petros)]
Current Pharmaceutical Design Pulmonary Hamartoma: Curative Laser Resection
Current Respiratory Medicine Reviews Regulation of Apolipoprotein B by Natural Products and Nutraceuticals: A Comprehensive Review
Current Medicinal Chemistry Salvianolic Acid A Attenuates Cell Apoptosis, Oxidative Stress, Akt and NF-κB Activation in Angiotensin-II Induced Murine Peritoneal Macrophages
Current Pharmaceutical Biotechnology Critical Roles of Insulin-Induced Senescence in Diabetic Vasculopathy
Vascular Disease Prevention (Discontinued) Dietary Nitrite in Nitric Oxide Biology: A Redox Interplay with Implications for Pathophysiology and Therapeutics
Current Drug Targets Platelet-derived Growth Factor Receptor-beta is Differentially Regulated in Primary Mouse Pericytes and Brain Slices
Current Neurovascular Research The Relevance of Microdialysis for Clinical Oncology
Current Clinical Pharmacology The HVJ-Envelope as an Innovative Vector System for Cardiovascular Disease
Current Gene Therapy Novel Therapeutic Targets for Management of Type-2 Diabetes Mellitus
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Cardiovascular Disease in Masked Hypertension: Clinical Implications
Current Hypertension Reviews Inducible Nitric Oxide Synthase as a Possible Target in Hypertension
Current Drug Targets Array-Comparative Genomic Hybridization Analysis of a Cohort of Saudi Patients with Epilepsy
CNS & Neurological Disorders - Drug Targets Thyrotoxic Periodic Paralysis: A Concise Review of the Literature
Current Rheumatology Reviews